FP-18, sodium salt A89856 (Previously 699856) (2R,3R,4R,5S,6R)-3-dodecanamido-4,5-bis(dodecanoyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl phosphate, sodium salt
FP-18, sodium salt (hereinafter: FP-18 sodium salt) is a semisynthetic, small-molecule, Toll-like receptor 4 (TLR4) agonist designed as a potent and reliable vaccine adjuvant. It promotes the release of type I interferons critical for antiviral immunity, in addition to activating signaling pathways that are both MyD88 and TRIF-dependent to induce the release of key pro-inflammatory cytokines, including TNFα, IL‑1β, and IL‑6.
Unlike plant-derived or saponin-based adjuvants, the structure of FP-18 sodium salt, by design, promotes factors essential for translational vaccine development, such as enabling consistent synthesis, reproducible purity, and minimal batch-to-batch variability.
FP-18 sodium salt mimics the immune-stimulating effects of natural LPS without the risk of endotoxin contamination. In preclinical models, it has generated strong Th1-biased immune responses and cooperation when combined with glycoprotein antigens. While FP-18 sodium salt is available for research use only, our Avanti Research™ team can scale it to meet larger study demands, and we offer sub-licensing options for broader development needs.
